Buffalo, N.Y.-based Roswell Park Comprehensive Cancer Center achieved an overall one-year survival rate of 92.6% after standardizing allogeneic hematopoietic cell transplant processes and workflows, according to a study published July 5 in Transplantation and Cellular Therapy.
The most recent data from the Center for International Blood and Marrow Transplant Research shows that the national one-year overall survival rate was 80% between 2017 and 2022.
The higher survival rate achieved by Roswell Park followed a 2024 systemwide redesign of cell transplant procedures. Changes included in the redesign were: a “shortened menu” of less toxic treatment regimens; standardized and prioritized patient-donor matching; post-transplant cyclophosphamide to reduce the incidence of graft-versus-host disease; expanded transplant access to patient populations not typically considered “good candidates”; and implementation of an early-discharge outpatient care model.
“Allogeneic transplant is one of the most complex medical procedures done today. However, despite that complexity, less — done well — beats more,” Shernan Holtan, MD, chief of blood and marrow transplant and co-first author of the study, said in a July 6 news release from Roswell Park. “Less toxic regimens, modern donor selection and the right use of cyclophosphamide gave our patients something extraordinary — a 90%-plus chance of being alive and well a year out.”
Read the full study here.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
